Neuphoria Therapeutics Inc. Comprehensive Income
Neuphoria Therapeutics Inc. (NEUP) reported Comprehensive Income of -$12.67 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-09-18
- Neuphoria Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$4.90M.
- Neuphoria Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$347.17K, a 103.14% decline year-over-year.
- Neuphoria Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $2.43M.
- Neuphoria Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$9.86M.
- Neuphoria Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2026 was -$12.67M.
- Neuphoria Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$201.10K.
- Neuphoria Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$15.45M.
- Neuphoria Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$22.42M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$5.25M derived: sum of 2 quarters · filed 2026-09-18 | -$2.81M derived: sum of 3 quarters · filed 2026-09-18 | -$12.67M 10-K · filed 2026-09-18 |
| 2026-03-31 | -$347.17K 10-Q · filed 2026-05-15 | $2.09M derived: sum of 2 quarters · filed 2026-05-15 | -$7.77M 10-Q · filed 2026-05-15 | -$15.59M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | $2.43M 10-Q · filed 2026-02-17 | -$7.42M 10-Q · filed 2026-02-17 | -$15.24M derived: sum of 3 quarters · filed 2026-09-18 | -$4.17M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | -$9.86M 10-Q · filed 2025-11-14 | -$17.67M derived: sum of 2 quarters · filed 2026-09-18 | -$6.61M derived: sum of 3 quarters · filed 2026-09-18 | -$9.84M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | -$7.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $3.25M derived: sum of 2 quarters · filed 2026-09-18 | $18.30K derived: sum of 3 quarters · filed 2026-09-18 | -$201.10K 10-K · filed 2026-09-18 |
| 2025-03-31 | $11.07M 10-Q · filed 2026-05-15 | $7.83M derived: sum of 2 quarters · filed 2026-05-15 | $7.62M 10-Q · filed 2026-05-15 | $5.15M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$3.23M 10-Q · filed 2026-02-17 | -$3.45M 10-Q · filed 2026-02-17 | -$5.92M derived: sum of 3 quarters · filed 2026-02-17 | -$9.26M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$219.41K 10-Q · filed 2025-11-14 | -$2.69M derived: sum of 2 quarters · filed 2025-11-14 | -$6.03M derived: sum of 3 quarters · filed 2025-11-14 | -$10.13M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$5.81M derived: sum of 2 quarters · filed 2025-09-29 | -$9.91M derived: sum of 3 quarters · filed 2025-09-29 | -$15.45M 10-K · filed 2025-09-29 |
| 2024-03-31 | -$3.34M 10-Q · filed 2025-05-20 | -$7.44M derived: sum of 2 quarters · filed 2025-05-20 | -$12.98M 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$4.10M 10-Q · filed 2025-02-14 | -$9.64M 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$5.54M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$22.42M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |